ALK is a therapeutic target for lethal sepsis

Area of Science:

• Immunology
• Molecular Biology
• Pathology

Background:

• Sepsis is a life-threatening condition with limited treatment options.
• Anaplastic lymphoma kinase (ALK), typically linked to cancer, is investigated for its role in innate immunity.

Purpose of the Study:

• To explore the function of anaplastic lymphoma kinase (ALK) in regulating innate immune responses during sepsis.
• To investigate the ALK pathway's involvement in STING-mediated immunity and its potential as a therapeutic target.

Main Methods:

• Genetic disruption of ALK expression in monocytes and macrophages.
• Investigating ALK's interaction with EGFR and downstream signaling pathways (AKT, IRF3, NF-κB).
• Evaluating the protective effects of ALK-STING pathway inhibition in mouse models of sepsis and endotoxemia.

Main Results:

• Genetic disruption of ALK reduced STING-mediated immune responses to cyclic dinucleotides.
• ALK directly interacts with EGFR, activating AKT phosphorylation and IRF3/NF-κB signaling.
• Inhibition of the ALK-STING pathway provided protection against lethal sepsis and endotoxemia in mice.
• The ALK pathway was found to be upregulated in human sepsis patients.

Conclusions:

• Anaplastic lymphoma kinase (ALK) plays a critical role in modulating innate immunity and inflammatory responses during sepsis.
• The ALK-STING pathway represents a promising therapeutic target for treating sepsis and other systemic inflammatory disorders.